Compare MAIA & FUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAIA | FUSE |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 48.0M |
| IPO Year | 2022 | N/A |
| Metric | MAIA | FUSE |
|---|---|---|
| Price | $2.16 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 622.1K | 77.1K |
| Earning Date | 11-07-2025 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,949,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.87 |
| 52 Week Low | $0.87 | $1.45 |
| 52 Week High | $2.74 | $25.00 |
| Indicator | MAIA | FUSE |
|---|---|---|
| Relative Strength Index (RSI) | 74.91 | N/A |
| Support Level | $1.49 | N/A |
| Resistance Level | $1.71 | N/A |
| Average True Range (ATR) | 0.16 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 99.99 | 0.00 |
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.